Search

everythinglearnresearchcommunity

for

Search:↓

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.

Baricitinib works better than methotrexate for severe alopecia areata.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.